Novartis says EU approves Ilaris to treat childhood arthritis
ZURICH (Reuters) - Novartis said on Tuesday its arthritis drug Ilaris was approved in the European Union to treat children aged two years and older.
Novartis said Ilaris is already sold for treating cryopyrin-associated periodic syndromes, a rare inflammatory disorder. Tuesday's approval is for active systemic juvenile idiopathic arthritis (SJIA), a debilitating disease that can affect a child's growth.
The United States approved Ilaris for children in May.
(Reporting By Katharina Bart)
- White House reverses, says Obama met uncle and lived with him during law school
- South Africa mourns Mandela, will bury him on December 15 |
- U.S. television, Twitter, alive with new version of 'Sound of Music'
- RPT-UPDATE 1-Ford leans on global Mustang to burnish overseas image
- Ford leans on global Mustang to burnish overseas image
Revered by millions as a beacon of hope against oppression and as an archetype of reconciliation, Nelson Mandela leaves behind a grieving nation. Video